Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate by JOHN FOLEY

By JOHN FOLEY

Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.

Published: October 30, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1HecZBE

from WordPress http://ift.tt/1OahtkB
via Hadi Aboukhater